Renal Cell Carcinoma

Renal cell carcinoma (RCC) is a malignant neoplasm arising from the epithelial cells of the renal tubules, most commonly the proximal convoluted tubules. It is the most frequent primary renal tumor in dogs and cats, accounting for approximately 1-2% of all canine neoplasms and 0.5-1% of feline neoplasms. RCC is typically unilateral and solitary, but can be bilateral or multifocal. It is characterized by local invasion into the renal parenchyma, potential extension into the renal vein and caudal vena cava, and metastasis to regional lymph nodes, lungs, liver, and bones. The tumor can be classified histologically into clear cell, granular, papillary, and sarcomatoid variants, with the clear cell type being most common in dogs. In cats, the papillary pattern is more frequently observed. RCC is a highly vascular tumor, often presenting with hematuria, flank pain, and a palpable abdominal mass. Early diagnosis is challenging due to nonspecific clinical signs, and prognosis is guarded, especially with advanced stage at diagnosis.

The exact etiology of renal cell carcinoma in veterinary patients remains largely unknown, but several risk factors have been identified. Genetic mutations, particularly in tumor suppressor genes (e.g., VHL, p53) and oncogenes (e.g., c-MET, EGFR), are implicated in human RCC and likely play a role in veterinary cases. Exposure to environmental carcinogens, such as tobacco smoke, asbestos, and certain hydrocarbons, has been suggested but not definitively proven in animals. Chronic renal inflammation or infection may predispose to neoplastic transformation, though this is not well-established. In dogs, certain breeds (e.g., German Shepherd, Golden Retriever) have a higher incidence, suggesting a hereditary component. In cats, no specific breed predisposition is noted, but older age is a significant risk factor. No viral or bacterial etiologies have been confirmed for spontaneous RCC in domestic animals.

Renal cell carcinoma is the most common primary renal neoplasm in dogs and cats, but it remains relatively rare overall. In dogs, it accounts for approximately 1-2% of all malignant tumors, with a median age of onset around 8-10 years. There is a slight male predominance in some studies. Breeds such as German Shepherds, Golden Retrievers, and Beagles appear to be overrepresented. In cats, RCC is less common than lymphoma, but it is the most common primary renal tumor, with a median age of 10-12 years. No strong breed or sex predilection is reported in cats. The incidence is higher in older animals, and there is no geographic or seasonal variation. Metastasis is present in 30-50% of dogs and 20-30% of cats at the time of diagnosis, with the lungs being the most common site.

Renal cell carcinoma arises from the epithelial cells of the renal tubules, most often the proximal convoluted tubules. The tumor grows as a solid mass within the renal cortex, often expanding into the medulla and distorting the renal architecture. As the tumor enlarges, it can invade the renal capsule, extend into the renal pelvis, and infiltrate the renal vein, potentially propagating into the caudal vena cava. This vascular invasion can lead to pulmonary embolism and metastasis. The tumor is highly vascular, with abnormal angiogenesis driven by vascular endothelial growth factor (VEGF) and other pro-angiogenic factors. This vascularity contributes to hematuria and the risk of hemorrhage. The neoplastic cells may also produce erythropoietin, leading to paraneoplastic polycythemia. As the tumor grows, it replaces functional renal parenchyma, leading to progressive renal insufficiency. Systemic effects include cachexia, anemia of chronic disease, and paraneoplastic syndromes such as hypercalcemia (due to parathyroid hormone-related protein) and hypertension (due to renin secretion or vascular compression). Metastasis occurs via hematogenous spread, most commonly to the lungs, but also to the liver, bones, and brain.

Predisposing factors for renal cell carcinoma include advanced age, with most cases occurring in middle-aged to older animals. Certain breeds, such as German Shepherds and Golden Retrievers, have a higher incidence, suggesting a genetic predisposition. Chronic renal disease, such as chronic interstitial nephritis, may increase the risk of neoplastic transformation, though this is not well-documented. Exposure to environmental carcinogens, including tobacco smoke and industrial chemicals, may be a risk factor, but evidence is limited. In cats, chronic kidney disease is common, but its association with RCC is unclear. Immunosuppression, whether due to disease or medication, may also predispose to tumor development. No specific dietary or management factors have been identified.

Clinical signs of renal cell carcinoma are often nonspecific and may be absent in early stages. Common presenting signs include hematuria (gross or microscopic), which may be intermittent, and abdominal pain or discomfort. A palpable abdominal mass may be detected on physical examination, particularly in larger tumors. As the tumor progresses, signs of chronic kidney disease may develop, including polyuria, polydipsia, weight loss, anorexia, lethargy, and vomiting. Paraneoplastic syndromes can cause additional signs: polycythemia may lead to ruddy mucous membranes and neurological signs; hypercalcemia can cause weakness, depression, and gastrointestinal signs; hypertension may result in retinal detachment or neurological deficits. In cases of vascular invasion, acute signs of pulmonary thromboembolism (dyspnea, tachypnea) or hindlimb edema may occur. Metastasis to the lungs may cause coughing or respiratory distress. In advanced stages, signs of systemic illness, such as fever and cachexia, are common.

Differential diagnoses for renal cell carcinoma include other primary renal tumors such as renal lymphoma, nephroblastoma, renal adenoma, and transitional cell carcinoma of the renal pelvis. Metastatic neoplasia to the kidney (e.g., from mammary or pulmonary tumors) should also be considered. Non-neoplastic conditions that can mimic RCC include renal cysts (simple or complex), renal abscess, granulomatous disease (e.g., fungal infection), and hydronephrosis. Chronic interstitial nephritis with fibrosis can also present as a renal mass on imaging. Key distinguishing features: Renal lymphoma often presents with bilateral renomegaly and is highly responsive to chemotherapy; nephroblastoma typically occurs in young animals; renal adenoma is benign and slow-growing; transitional cell carcinoma often involves the renal pelvis and may cause hematuria with malignant cells in urine. Renal cysts are usually anechoic on ultrasound, whereas RCC is solid and vascular. Abscesses may have a thick wall and internal debris, and the animal may be febrile. Hydronephrosis shows a dilated renal pelvis with a thin cortex. Definitive diagnosis requires cytology or histopathology.

The diagnostic approach to a suspected renal mass begins with a thorough history and physical examination, including abdominal palpation. Initial laboratory tests include a complete blood count (CBC), serum biochemistry profile, urinalysis, and urine culture. If a renal mass is suspected, abdominal ultrasonography is the next step to confirm the presence of a mass, assess its characteristics (echogenicity, vascularity), and evaluate the contralateral kidney and regional lymph nodes. Thoracic radiographs (three views) are essential to screen for pulmonary metastases. If the mass is solid and vascular, fine-needle aspiration (FNA) under ultrasound guidance can be performed for cytology, though it may be nondiagnostic. For a definitive diagnosis, a surgical biopsy (incisional or excisional) is recommended. Advanced imaging such as computed tomography (CT) or magnetic resonance imaging (MRI) is valuable for surgical planning, especially to assess vascular invasion and metastasis. If vascular invasion is suspected, Doppler ultrasound or CT angiography is indicated. Staging should include abdominal ultrasound, thoracic radiographs or CT, and possibly abdominal CT to assess local invasion and lymph node involvement. If the tumor is confirmed, histopathology is essential to determine the subtype and grade, which have prognostic significance.

Hematology: In many cases, the CBC is unremarkable. However, paraneoplastic polycythemia may be present, resulting in increased hematocrit, hemoglobin, and red blood cell count. Anemia of chronic disease may also occur, characterized by normocytic, normochromic anemia. Leukocytosis may be seen due to inflammation or stress. Serum biochemistry: Azotemia (elevated BUN and creatinine) may be present if the tumor has caused significant loss of renal function, especially if bilateral or if the contralateral kidney is compromised. Hypercalcemia may be present due to paraneoplastic secretion of parathyroid hormone-related protein. Liver enzymes may be elevated if there is metastatic disease. Electrolyte imbalances, such as hyperkalemia or hyponatremia, may occur with renal dysfunction. Urinalysis: Hematuria (gross or microscopic) is common. Proteinuria may be present, and the urine specific gravity may be isosthenuric if renal function is impaired. Urine sediment may contain neoplastic cells, but this is not a sensitive or specific finding. Urine culture should be performed to rule out urinary tract infection. Blood gas analysis: May reveal metabolic acidosis if renal failure is advanced. Specific biomarkers: SDMA (symmetric dimethylarginine) may be elevated earlier than creatinine in chronic kidney disease. Other biomarkers such as erythropoietin levels may be elevated in cases of polycythemia. Serology/PCR: Not typically indicated unless infectious causes are suspected.

Radiography: Abdominal radiographs may reveal a soft tissue mass in the renal area, with loss of the normal renal silhouette. The mass may cause displacement of adjacent organs. Thoracic radiographs are essential to detect pulmonary metastases, which appear as nodular interstitial patterns. Ultrasonography: On ultrasound, RCC typically appears as a solid, hypoechoic to isoechoic mass within the renal parenchyma, often with a heterogeneous echotexture due to areas of necrosis, hemorrhage, or mineralization. The mass may distort the normal renal architecture. Color Doppler may show increased vascularity. The renal vein and caudal vena cava should be evaluated for tumor thrombi, which appear as echogenic material within the vessel lumen. The contralateral kidney should be assessed for size and echogenicity. Computed Tomography (CT): CT provides excellent detail of the renal mass, including its extent, invasion into surrounding tissues, and vascular involvement. Triple-phase contrast-enhanced CT can assess tumor enhancement and detect thrombi. CT is also superior for staging metastatic disease, particularly in the lungs. Magnetic Resonance Imaging (MRI): MRI may be used for further characterization of the mass and to evaluate vascular invasion, but it is less commonly used than CT. Endoscopy and fluoroscopy are not typically used for renal masses.

Fine-needle aspiration (FNA) cytology: FNA of a renal mass may yield cells with moderate to marked anisocytosis and anisokaryosis, prominent nucleoli, and variable amounts of cytoplasm. The cells may be arranged in clusters or acini. However, FNA has limited sensitivity and specificity, and a negative result does not rule out malignancy. Histopathology: Definitive diagnosis requires biopsy. On histopathology, RCC is characterized by a proliferation of tubular epithelial cells with varying degrees of atypia. The tumor may exhibit solid, tubular, papillary, or cystic patterns. Clear cell carcinoma shows cells with abundant clear cytoplasm due to glycogen and lipid content. Granular cell carcinoma has eosinophilic granular cytoplasm. Sarcomatoid variants have spindle-shaped cells. Immunohistochemistry can be used to confirm the epithelial origin (positive for cytokeratin, negative for vimentin). The tumor may show invasion into the renal capsule, renal vein, or lymphatics. Histologic grading (based on nuclear atypia, mitotic count, and necrosis) has prognostic significance.

The primary treatment for renal cell carcinoma is surgical excision, typically via unilateral nephrectomy. Preoperative staging is essential to rule out metastasis and assess the function of the contralateral kidney. If the tumor is confined to the kidney and there is no evidence of metastasis, nephrectomy can be curative. In cases of vascular invasion, the tumor thrombus should be removed if possible, but this may require advanced surgical techniques. If the tumor is inoperable or metastatic disease is present, treatment is palliative. Chemotherapy has limited efficacy in RCC, but drugs such as doxorubicin, carboplatin, and toceranib phosphate (a tyrosine kinase inhibitor) may be considered. Toceranib has shown some activity in canine RCC. Radiation therapy may be used for pain control or to treat metastatic lesions, but RCC is generally considered radioresistant. Supportive care includes management of renal insufficiency (e.g., fluid therapy, dietary modification, phosphate binders, erythropoietin for anemia), control of hypertension (e.g., amlodipine), and treatment of paraneoplastic syndromes (e.g., hypercalcemia with bisphosphonates or saline diuresis). Pain management with analgesics (e.g., NSAIDs, opioids) is important. Nutritional support may be needed for cachexia.

The prognosis for renal cell carcinoma is guarded to poor, depending on the stage at diagnosis and the completeness of surgical excision. For dogs with localized disease treated with nephrectomy, median survival times range from 6 to 12 months, with some dogs living longer. Factors associated with a worse prognosis include the presence of metastasis, vascular invasion, high histologic grade, and sarcomatoid differentiation. In cats, the prognosis is similarly guarded, with median survival times of 6 to 12 months after nephrectomy. Paraneoplastic syndromes, such as polycythemia or hypercalcemia, may resolve after tumor removal but can recur with metastasis. The overall metastatic rate is high, with up to 50% of dogs and 30% of cats developing metastasis. Early detection and surgical intervention offer the best chance for prolonged survival, but recurrence is possible.

After nephrectomy, patients should be monitored closely for recurrence and metastasis. A recheck examination, including physical examination, blood work (CBC, biochemistry, SDMA), and urinalysis, is recommended at 1, 3, and 6 months post-surgery, then every 3-6 months thereafter. Thoracic radiographs should be repeated every 3-6 months to screen for pulmonary metastases. Abdominal ultrasound should be performed every 3-6 months to assess the remaining kidney and check for local recurrence or abdominal metastasis. Blood pressure should be monitored regularly, as hypertension may develop or persist. Renal function should be assessed periodically, especially if the contralateral kidney was compromised. If the patient is receiving chemotherapy or toceranib, more frequent monitoring is required, including CBC and biochemistry to assess for toxicity. Adjustments to medications (e.g., antihypertensives, phosphate binders) should be made based on laboratory results and clinical status.

Pearls: 1. Always perform a thorough abdominal palpation in older dogs and cats, as a renal mass may be palpable. 2. Hematuria in an older animal should prompt imaging of the urinary tract, including the kidneys. 3. Ultrasonography is the most useful initial imaging modality for a renal mass; Doppler can detect vascular invasion. 4. If a renal mass is found, always stage the patient with thoracic radiographs and abdominal ultrasound before surgery. 5. Consider paraneoplastic syndromes: polycythemia, hypercalcemia, and hypertension. 6. Nephrectomy is the treatment of choice for localized disease; ensure the contralateral kidney is functional. Pitfalls: 1. Do not rely solely on FNA cytology for diagnosis, as it can be falsely negative. 2. Avoid nephrectomy without staging, as metastasis may be present. 3. Do not overlook the possibility of a tumor thrombus in the renal vein or vena cava, which can be missed on ultrasound if not specifically evaluated. 4. Do not assume a renal mass is benign; even small masses can be malignant. 5. Do not forget to monitor blood pressure and renal function post-operatively, as the remaining kidney may be compromised.

Chemotherapy: Doxorubicin: 30 mg/m² IV every 3 weeks (dogs); 1 mg/kg IV every 3 weeks (cats). Carboplatin: 300 mg/m² IV every 3 weeks (dogs); 200 mg/m² IV every 3 weeks (cats). Toceranib phosphate (Palladia): 3.25 mg/kg PO every other day (dogs). Supportive care: For hypertension, amlodipine: 0.1-0.2 mg/kg PO q24h (dogs and cats). For hypercalcemia, saline diuresis (0.9% NaCl at 60-100 ml/kg/day IV) and furosemide (1-2 mg/kg IV or PO q8-12h) may be used; bisphosphonates such as pamidronate (1-2 mg/kg IV over 2 hours) or alendronate (1-2 mg/kg PO q24h) can be considered. For anemia, erythropoietin (100 U/kg SC three times weekly) or darbepoetin (1 μg/kg SC once weekly) may be used, but with caution. For pain, NSAIDs (e.g., carprofen 2.2 mg/kg PO q12h, meloxicam 0.1 mg/kg PO q24h) or opioids (e.g., tramadol 2-5 mg/kg PO q8-12h) can be used. For renal insufficiency, phosphate binders (e.g., aluminum hydroxide 30-100 mg/kg/day PO divided with meals) and a renal diet are recommended. All dosages should be adjusted based on renal function and patient status.

Renal cell carcinoma in dogs and cats is a relatively rare but well-documented neoplasm. A retrospective study by Bryan et al. (2006) evaluated 50 dogs with primary renal tumors, of which 60% were RCC. Median survival time for dogs with RCC treated with nephrectomy was 16 months, with a 1-year survival rate of 60%. Factors associated with shorter survival included the presence of metastasis, vascular invasion, and high histologic grade. Another study by Henry et al. (1999) reported a median survival of 8 months for dogs with RCC, with a metastatic rate of 50%. In cats, a study by Buracco et al. (2002) found a median survival of 12 months after nephrectomy, with a metastatic rate of 30%. Chemotherapy has shown limited efficacy, but toceranib has demonstrated activity in some canine cases (London et al., 2012). The ACVIM consensus statement on the diagnosis and treatment of renal tumors in dogs and cats (2016) recommends surgical excision as the primary treatment, with staging including thoracic radiographs and abdominal ultrasound. The use of tyrosine kinase inhibitors is considered for unresectable or metastatic disease. Overall, the literature supports early detection and aggressive surgical intervention for the best prognosis.